FDA blocks much-anticipated BioMarin hemophilia gene therapy

National and World

BioMarin now will have to complete an ongoing late-stage patient study, delaying possible approval till late 2022

Health, Medical Generic

Credit: pagadesign/SEAN GLADWELL/Moment/Getty Images

FAIRLESS HILLS, PA (AP) – BioMarin Pharmaceutical shares plunged by a third after U.S. regulators rejected its potentially game-changing gene therapy for hemophilia A patients.

The Food and Drug Administration late Tuesday raised concerns Roctavian might not really be a one-and-done lifetime treatment, so it wants study participants to be followed longer.

BioMarin now will have to complete an ongoing late-stage patient study, delaying possible approval till late 2022.

The therapy could have freed hemophilia A patients from frequent, extremely expensive IV infusions of blood-clotting therapy to prevent internal bleeding from the rare genetic disorder.

Questions about how long Roctavian works arose recently amid suggestions the company could charge up to $3 million per patient.

(Copyright 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.)

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending on WKBN.com